Skip to main content
Terug
Watch Compare

Aspire Biopharma Holdings, Inc.

Datakwaliteit: 100%
Ook genoteerd als ASBPW NASDAQ
ASBP
NASDAQ Manufacturing Chemicals
€ 0,61
▼ € 0,59 (-49,16%)
6 months return
—
Momentum
Neutral
Net margin
-394725,06%

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROICN/A
Net Margin-394725,06%
Op. Margin-312016,95%

Veiligheid

Debt / Equity
N/A
Current Ratio0,17
Interest Coverage-2,27

Waardering

PE (TTM)
-0,25
Boven sectorgemiddelde (-1,50)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -4,92 M

Price History

Financiële Trends

Koersdoel Analisten

Geen analistendekking beschikbaar

Growth

Rev 5Y: N/A · Earnings 1Y: N/A
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A

Profitability

ROE: N/A · Net Margin: -394725,06%
Revenue (TTM) 6.202,0 Net Income (TTM) -24,48 M
ROE N/A ROA -1443,21%
Gross Margin -1,87% Operating Margin -312016,95%
Net Margin -394725,06% Free Cash Flow (TTM) -4,92 M
ROIC N/A FCF Growth (3Y) N/A

Safety

D/E: N/A · Current: 0,17
Debt / Equity N/A Current Ratio 0,17
Interest Coverage -2,27 Asset Turnover 0,00
Working Capital -11,46 M Tangible Book Value -11,47 M

Dividends

Yield: N/A · Payout: N/A
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A

Valuation

P/E: -0,25 · EV/EBITDA: N/A
P/E Ratio -0,25 Forward P/E N/A
P/B Ratio N/A P/S Ratio 972,10
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -81,66%
Market Cap 6,03 M Enterprise Value 6,03 M

Per Share

EPS: -16,38 · FCF/Share: -0,98
EPS (Diluted TTM) -16,38 Revenue / Share 0,00
FCF / Share -0,98 OCF / Share -0,98
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A

Efficiency

FCF Conv: 20,11% · CapEx/Rev: N/A
CapEx / Revenue N/A FCF Conversion 20,11%
SBC-Adj. FCF -19,05 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue 6.202,0 — — —
Net Income -24,48 M -12,54 M 4,46 M 3,34 M
EPS (Diluted) -16,38 — — —
Gross Profit -116,0 — — —
Operating Income -19,35 M — — —
EBITDA — — — —
R&D Expenses 923.914,0 — — —
SG&A Expenses — — — —
D&A — — — —
Interest Expense 8,53 M 891.624,0 8.966,0 —
Income Tax 1.013,0 — — —

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 1,31 M 6,71 M 19,98 M 300,18 M
Total Liabilities 7,69 M 15,62 M 403.328,0 11,12 M
Shareholders' Equity -6,38 M -15,57 M -322.105,0 -9,94 M
Total Debt — — — —
Cash & Equivalents — — — —
Current Assets 1,31 M 45.842,0 81.223,0 1,10 M
Current Liabilities 7,59 M 15,62 M 403.328,0 303.323,0

Sectorvergelijking

vs Manufacturing sector mediaan (1605 peers)
Metriek Aandeel Sector Mediaan
P/E -0,3 -1,5
P/B — 1,6
ROE % — -54,7
Net Margin % -394725,1 -41,5
Rev Growth 5Y % — 1,7
D/E — 0,3